Alzheimer's filament

Researchers at the Salk Institute and the University of Lausanne workingwith pharmaceutical company Roche have solved the three-dimensionalstructure of the long thread-like fibers that are present in the braintissue of Alzheimer's disease patients. The structure reveals thattheses proteins zipper together to make the fibrils, a process thatmight be a target for novel drugs to combat the debilitating effects ofthe disease. Salk's Roland Riek says that the study will primarily helpexplain how one drug currently in European clinical trials works.Apparently, the drug binds to the end of the fibril chain of betaamyloid proteins and stops them accumulating to form the telltaleamyloid plaques of Alzheimer's disease.